United States, Nevada, Las Vegas, DelveInsight’s ‘Deep Vein Thrombosis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Deep Vein Thrombosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Deep Vein Thrombosis pipeline domain.
Key Takeaways from the Deep Vein Thrombosis Pipeline Report
- Over 5+ Deep Vein Thrombosis pipeline therapies are in various stages of development, and their anticipated acceptance in the Deep Vein Thrombosis market would significantly increase market revenue.
- Leading Deep Vein Thrombosis companies developing novel drug candidates to improve the Deep Vein Thrombosis treatment landscape include Carbomimetics, Anthos Therapeutics, and others.
- Promising Deep Vein Thrombosis pipeline therapies in various stages of development include CM20201, Abelacimab, and others.
Deep Vein Thrombosis Overview
Deep vein thrombosis (DVT) is a medical condition that occurs when a blood clot forms in a deep vein. These clots usually develop in the lower leg, thigh, or pelvis, but they can also occur in the arm. The most serious complication of DVT happens when a part of the clot breaks off and travels through the bloodstream to the lungs, causing a blockage called pulmonary embolism (PE). If the clot is small, and with appropriate treatment, people can recover from PE. However, there could be some damage to the lungs. If the clot is large, it can stop blood from reaching the lungs and is fatal. Medication is used to prevent and treat DVT. Compression stockings (also called graduated compression stockings) are sometimes recommended to prevent DVT and relieve pain and swelling. These might need to be worn for 2 years or more after having DVT. In severe cases, the clot might need to be removed surgically.
Deep Vein Thrombosis Pipeline Analysis: Drug Profile
Currently in the preclinical phase, CM20201, an efficient small glyco-drug with selective activity inhibition of Factor Xa, would be used in a first place for oncology related Deep Vein Thrombosis (DVT). Today, anticoagulants are the reference treatment but display major risk of uncontrollable life threatening bleeding.
Discover more about the emerging Deep Vein Thrombosis drugs @ Deep Vein Thrombosis Treatment Drugs
Deep Vein Thrombosis Key Companies
- Anthos Therapeutics
Deep Vein Thrombosis Pipeline Therapies
Deep Vein Thrombosis Pipeline Therapeutics Assessment
- By development stage
- By product type
- By route of administration
- By molecule type
- By MOA type
Scope of the Deep Vein Thrombosis Pipeline Report
- Coverage: Global
- Key Deep Vein Thrombosis Companies: Carbomimetics, Anthos Therapeutics, and others
- Key Deep Vein Thrombosis Pipeline Therapies: CM20201, Abelacimab, and others
Find out more about the Deep Vein Thrombosis treatment options in development @ Deep Vein Thrombosis Treatment Algorithm
Table of Contents
2. Executive Summary
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
16. About DelveInsight
Request for a sample report to know more about the key companies working in the Deep Vein Thrombosis Pipeline Segment
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States